FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 355:2252-2253 November 23, 2006 Number 21 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Perspective by Hiatt, W. R. Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

In January 2006, we published an article by Mangano and colleagues¹ that reported the results of an observational study of antifibrinolytic agents to control bleeding in cardiac surgery. The data suggested that patients treated with aprotinin, as compared with no antifibrinolytic agent, aminocaproic acid, or tranexamic acid, had higher risks of a number of adverse events, including cardiovascular events (myocardial infarction, heart failure, and stroke) and renal failure requiring dialysis. The study data were from a prospective registry funded by the Ischemia Research and Education Foundation. As detailed by Hiatt in a Perspective article in this issue of the Journal, . . . [Full Text of this Article]

Related Letters:

Judging the Safety of Aprotinin
Mangano D. T., Rieves R. D., Weiss K. D.
Extract | Full Text | PDF  
N Engl J Med 2006; 355:2261-2262, Nov 23, 2006. Correspondence

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.